Literature DB >> 6571798

Acute cerebellar dysfunction with high-dose ARA-C therapy.

M C Salinsky, R L Levine, J P Aubuchon, H S Schutta.   

Abstract

The authors report a patient with clinical and morphologic evidence of acute cerebellar toxicity after receiving high-dose cytosine arabinoside (ARA-C) (3000 mg/m2/12 hours) for refractory AML. Damage of Purkinje cells and dentate nucleus was demonstrated. Reversible cerebellar toxicity has previously been noted in patients on an identical regimen. Signs of cerebellar dysfunction mandate immediate cessation of high-dose ARA-C therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6571798     DOI: 10.1002/1097-0142(19830201)51:3<426::aid-cncr2820510312>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

2.  Successful treatment of cytarabine-related neurotoxicity with corticosteroids, a case series.

Authors:  Jennifer L Dotson; Muhammad Omer Jamil
Journal:  Int J Hematol       Date:  2018-06-26       Impact factor: 2.490

Review 3.  Drug-induced aseptic meningitis: diagnosis and management.

Authors:  S Jolles; W A Sewell; C Leighton
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

Review 4.  Cerebellar toxicity during cytarabine therapy associated with renal insufficiency.

Authors:  H Hasle
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Brain perfusion in adult patients with acute myeloblastic leukemia before and after cytosine arabinoside.

Authors:  Romain Modzelewski; Stéphane Lepretre; Olivier Martinaud; Didier Hannequin; Anne Hitzel; Marie-Odile Habert; Hervé Tilly; Pierre Vera
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

6.  Minor changes on cranial MRI during treatment in children with acute lymphoblastic leukaemia.

Authors:  E Pääkkö; L Vainionpää; J Pyhtinen; M Lanning
Journal:  Neuroradiology       Date:  1996-04       Impact factor: 2.804

Review 7.  The toxicity of cytarabine.

Authors:  J Stentoft
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

8.  Cerebellar sclerosis in pediatric cancer patients.

Authors:  M Wizniter; R J Packer; L B Rorke; A T Meadows
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

9.  AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.

Authors:  L H Lindner; H Ostermann; W Hiddemann; A Kiani; M Würfel; T Illmer; C Karsch; U Platzbecker; G Ehninger; E Schleyer
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490

10.  Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia.

Authors:  E R Grümayer; W Schmidmeier; S Panzer; H Gadner
Journal:  Blut       Date:  1986-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.